WHO calls for better accessibility to psoriasis treatments
As part of the "Global Report on Psoriasis," the World Health Organization (WHO) recently called for improved accessibility to psoriasis treatments for patients.
The WHO has stated that it is up to policymakers and governments to make the needed improvements with respect to psoriasis treatment accessibility. This is an important part of helping psoriasis patients around the world, lightening their burden as well as their community’s.
“Too many people in the world suffer needlessly from psoriasis due to incorrect or delayed diagnosis, inadequate treatment options and insufficient access to care,” according to the WHO report.
Psoriasis is a skin disorder. When skin cells multiple much more rapidly than usual, patients develop raised, red plaques, which characterize psoriasis. Unfortunately, it is more than a simple rash. Psoriasis decreases lifespans because of its multiple comorbidities: patients have a significantly higher chance of developing metabolic syndrome, cardiovascular disease and mental health disorders. People with psoriasis as well as arthritis have a particularly difficult time with unemployment and disability, as well.
“Like many diseases, there is ample need to continue to educate and raise awareness about psoriasis as a chronic, systemic disease,” Lindsay Bohlander, associate director of patient advocacy at Celgene, said.
To resolve this problem, the WHO has made several recommendations for psoriasis patients. The organization recommends that health professionals scan these patients for more than skin concerns, remaining on the lookout for other significant health concerns.
“Implementation of the WHO’s recommendations is imperative for psoriasis patients,” Bohlander said. “To truly make an impact for psoriasis patients to gain the access to care and treatment they need, it will take all stakeholders to become vested in their health and care.”
Organizations in this story
Celgene Corporation 86 Morris Ave Summit, NJ - 07901